GIP and GLP-1 receptor co-agonist
BGM0504 5 mg injection once weekly
BGM050_SC_5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.69 (0.01 to 59.39) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.12 (0.20 to 75.86) | 0.21 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 9.38 (0.33 to 266) | 0.19 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 9.21 (1.97 to 44.17) | 0.06 |